167 related articles for article (PubMed ID: 37180173)
21. Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study.
Wu JY; Zhang ZB; Zhou JY; Ke JP; Bai YN; Chen YF; Wu JY; Zhou SQ; Wang SJ; Zeng ZX; Li YN; Qiu FN; Li B; Yan ML
Liver Cancer; 2023 Aug; 12(3):229-237. PubMed ID: 37767067
[TBL] [Abstract][Full Text] [Related]
22. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
Ando Y; Kawaoka T; Amioka K; Naruto K; Ogawa Y; Yoshikawa Y; Kikukawa C; Kosaka Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2021; 99(8):507-517. PubMed ID: 33946070
[TBL] [Abstract][Full Text] [Related]
25. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
Yang X; Chen B; Wang Y; Wang Y; Long J; Zhang N; Xue J; Xun Z; Zhang L; Cheng J; Lei J; Sun H; Li Y; Lin J; Xie F; Wang D; Pan J; Hu K; Guan M; Huo L; Shi J; Yu L; Zhou L; Zhou J; Lu Z; Yang X; Mao Y; Sang X; Lu Y; Zhao H
Hepatol Int; 2023 Jun; 17(3):709-719. PubMed ID: 36753026
[TBL] [Abstract][Full Text] [Related]
26. Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.
Zhang W; Zhang K; Liu C; Gao W; Si T; Zou Q; Guo Z; Yang X; Li M; Liu D; Mu H; Li H; Yu H; Xing W
Front Immunol; 2023; 14():1127349. PubMed ID: 37180098
[TBL] [Abstract][Full Text] [Related]
27. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman OM; Elsayed Z
Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
[TBL] [Abstract][Full Text] [Related]
28. Neutrophil-to-Lymphocyte Ratio and Early Tumor Shrinkage as Predictive Biomarkers in Unresectable Hepatocellular Carcinoma Patients Treated With Lenvatinib, PD-1 Inhibitors, in Combination With TACE.
Qu S; Wu D; Hu Z
Technol Cancer Res Treat; 2023; 22():15330338231206704. PubMed ID: 37849287
[No Abstract] [Full Text] [Related]
29. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
30. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study.
Ren Y; Cao Y; Ma H; Kan X; Zhou C; Liu J; Shi Q; Feng G; Xiong B; Zheng C
BMC Cancer; 2019 Oct; 19(1):983. PubMed ID: 31640620
[TBL] [Abstract][Full Text] [Related]
31. Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate.
Dohmen K; Shirahama M; Shigematsu H; Miyamoto Y; Torii Y; Irie K; Ishibashi H
Hepatogastroenterology; 2001; 48(41):1409-15. PubMed ID: 11677976
[TBL] [Abstract][Full Text] [Related]
32. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma.
Dai L; Cai X; Mugaanyi J; Liu Y; Mao S; Lu C; Lu C
Sci Rep; 2021 Oct; 11(1):19711. PubMed ID: 34611195
[TBL] [Abstract][Full Text] [Related]
34. Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability of treatment weighting analysis.
Tong Y; Cai R; Li JX; Chang DH; Wang LZ; Cai WW; Xiao YD
Aliment Pharmacol Ther; 2022 Dec; 56(11-12):1602-1614. PubMed ID: 36285593
[TBL] [Abstract][Full Text] [Related]
35. Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice.
Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1679. PubMed ID: 35822407
[TBL] [Abstract][Full Text] [Related]
36. Transarterial Chemoembolization Combined With Apatinib Plus PD-1 Inhibitors for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
Xia WL; Zhao XH; Guo Y; Hu HT; Cao GS; Li Z; Fan WJ; Xu SJ; Li HL
Clin Transl Gastroenterol; 2023 May; 14(5):e00581. PubMed ID: 36920551
[TBL] [Abstract][Full Text] [Related]
37. Preoperative transcatheter arterial chemoembolization for surgical resection of huge hepatocellular carcinoma (≥ 10 cm): a multicenter propensity matching analysis.
Li C; Wang MD; Lu L; Wu H; Yu JJ; Zhang WG; Pawlik TM; Zhang YM; Zhou YH; Gu WM; Wang H; Chen TH; Han J; Xing H; Li ZL; Lau WY; Wu MC; Shen F; Yang T
Hepatol Int; 2019 Nov; 13(6):736-747. PubMed ID: 31486964
[TBL] [Abstract][Full Text] [Related]
38. Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial.
Lee TY; Lin CC; Chen CY; Wang TE; Lo GH; Chang CS; Chao Y
Medicine (Baltimore); 2017 Sep; 96(37):e7655. PubMed ID: 28906355
[TBL] [Abstract][Full Text] [Related]
39. Comparison of combination therapies in the management of hepatocellular carcinoma: transarterial chemoembolization with radiofrequency ablation versus microwave ablation.
Ginsburg M; Zivin SP; Wroblewski K; Doshi T; Vasnani RJ; Van Ha TG
J Vasc Interv Radiol; 2015 Mar; 26(3):330-41. PubMed ID: 25534635
[TBL] [Abstract][Full Text] [Related]
40. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma.
Liu B; Zhang Y; Chen H; Li W; Tsochatzis E
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013345. PubMed ID: 34981511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
